Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease
- PMID: 17023091
- DOI: 10.1016/j.neuint.2006.08.012
Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease
Abstract
Kynurenine aminotransferases (KAT I and KAT II) are responsible for the transamination of kynurenine (KYN) to form kynurenic acid (KYNA), an excitatory amino acid receptor antagonist. Since these members of the kynurenine pathway (KP) are proposed to be involved in the pathogenesis of Alzheimer's dementia (AD), the activities of these enzymes and the levels of these metabolites were measured in the plasma and red blood cells (RBCs) of AD and control subjects together with the inheritance of the apolipoprotein (APOE) epsilon4 allele. KYNA levels were significantly decreased both in the plasma and in the RBCs in AD, but the levels of KYN and the activities of KAT I and KAT II remained unchanged. No association has been found with the possession of the epsilon4 allele. These findings indicate an altered peripheral KP in AD regardless of the APOE status of the probands.
Similar articles
-
Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease.J Neurol Sci. 2005 Dec 15;239(1):31-5. doi: 10.1016/j.jns.2005.07.006. Epub 2005 Aug 15. J Neurol Sci. 2005. PMID: 16099471
-
Kynurenine metabolism in Alzheimer's disease.J Neural Transm (Vienna). 1999;106(2):165-81. doi: 10.1007/s007020050149. J Neural Transm (Vienna). 1999. PMID: 10226937
-
Kynurenine metabolism in multiple sclerosis.Acta Neurol Scand. 2005 Aug;112(2):93-6. doi: 10.1111/j.1600-0404.2005.00442.x. Acta Neurol Scand. 2005. PMID: 16008534
-
Kynurenic acid and kynurenine aminotransferases in retinal aging and neurodegeneration.Pharmacol Rep. 2011;63(6):1324-34. doi: 10.1016/s1734-1140(11)70697-1. Pharmacol Rep. 2011. PMID: 22358081 Review.
-
The role of glutamine transaminase K (GTK) in sulfur and alpha-keto acid metabolism in the brain, and in the possible bioactivation of neurotoxicants.Neurochem Int. 2004 Jun;44(8):557-77. doi: 10.1016/j.neuint.2003.12.002. Neurochem Int. 2004. PMID: 15016471 Review.
Cited by
-
Kynurenine Metabolism and Alzheimer's Disease: The Potential Targets and Approaches.Neurochem Res. 2022 Jun;47(6):1459-1476. doi: 10.1007/s11064-022-03546-8. Epub 2022 Feb 8. Neurochem Res. 2022. PMID: 35133568 Review.
-
All roads lead to Rome - a review of the potential mechanisms by which exerkines exhibit neuroprotective effects in Alzheimer's disease.Neural Regen Res. 2022 Jun;17(6):1210-1227. doi: 10.4103/1673-5374.325012. Neural Regen Res. 2022. PMID: 34782555 Free PMC article. Review.
-
Decrypting the Possible Mechanistic Role of Fenofibrate in Alzheimer's Disease and Type 2 Diabetes: The Truth and Mystery.J Cell Mol Med. 2025 Mar;29(5):e70378. doi: 10.1111/jcmm.70378. J Cell Mol Med. 2025. PMID: 40040308 Free PMC article. Review.
-
The Biology and Biochemistry of Kynurenic Acid, a Potential Nutraceutical with Multiple Biological Effects.Int J Mol Sci. 2024 Aug 21;25(16):9082. doi: 10.3390/ijms25169082. Int J Mol Sci. 2024. PMID: 39201768 Free PMC article. Review.
-
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?CNS Neurosci Ther. 2022 Jan;28(1):19-35. doi: 10.1111/cns.13768. Epub 2021 Dec 3. CNS Neurosci Ther. 2022. PMID: 34862742 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous